Advertisement

NYMX

Nymox Pharmaceutical Corporation

Healthcare

Set alert

Price alert · NYMX

All alert types
0.20 0.00 0.00%
As of Jul 6, 2023
0.1999 Day range 0.1999

52-week range unavailable

Open
0.22
Prev close
0.1999
Mkt cap
18.25M
Vol
881.57K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
0.1999
High
0.1999
Forward P/E
0.00
Beta
0.65
Short ratio
59.73
Inst. own
1.12%
Dividend
0.00
Ex-div date
Earnings
May 12, 2023
50-d avg
0.385079
200-d avg
0.385119
1y target
10.25

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for NYMX has not been loaded yet. Try again in a moment.

Key statistics

Market cap
18.25M
Enterprise value
17.87M
Trailing P/E
0.00
Forward P/E
0.00
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
EPS (TTM)
-0.02
Beta
0.65
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-998.04K
Total cash
351.00K
Total debt
114.00K
Return on equity
0.00%
Shares outstanding
91.27M
Short % of float
4.65%
50-day average
0.385079
200-day average
0.385119

Analyst view

Consensus: none

Price target (mean) 10.25

Next earnings

May 12, 2023

Expected May 12, 2023. Consensus EPS estimate 0.00.

Earnings history

Earnings

NYMX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 12, 2023Mar 1, 20230.00———
May 1, 2023Dec 1, 20220.00———
Nov 14, 2022Sep 1, 20220.00———
Aug 15, 2022Jun 1, 20220.00———
May 13, 2022Mar 1, 20220.00———
Mar 30, 2022Dec 1, 20210.00———

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

Sector
Healthcare
Industry
Biotechnology
Country
Bahamas
Website
nymox.com

News

Your note

Sign in to keep a note on NYMX — it syncs with the Stock Master app.

Insider holders

NYMX insider holders
InsiderRelationLatest transactionDateShares held
AVERBACK PAULChief Executive OfficerSaleOct 28, 201821,643,900
DANIELSEN ERIKChief Financial OfficerPurchaseDec 20, 201820,900
LANHAM RANDALL J ESQ.General CounselPurchaseOct 25, 2018152,900
ROBINSON JAMES GEORGEDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseApr 26, 20234,782,060

Institution ownership

NYMX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.0.15%135,61227.12KMar 30, 2023
Cetera Advisor Networks LLC0.13%118,90023.78KMar 30, 2023
Morgan Stanley0.11%98,68619.74KMar 30, 2023
Simplicity Solutions, LLC0.09%80,00016.00KMar 30, 2023
Bleakley Financial Group, LLC 0.09%80,00016.00KMar 30, 2023
Renaissance Technologies, LLC0.08%69,38113.88KMar 30, 2023

Fund ownership

NYMX fund ownership
Holder% heldSharesValueReported
iShares Micro Cap ETF0.12%112,23822.45KFeb 27, 2023
Fidelity NASDAQ Composite Index Fund0.06%50,67810.13KFeb 27, 2023
EQ Advisors Trust-1290 VT Micro Cap Port0.01%9,3181.86KDec 30, 2022
Master Investment Portfolio-Diversified Equity Master Portfolio0.01%5,6851.14KDec 30, 2022
Advertisement